Dallas, TX 9/26/2011 10:54:48 PM
News / Stocks

WRAP, RXPC, AGEN are included in our Top Penny Stock Gainers

WRAP, RXPC, AGEN are some of today’s top penny stock gainers.

WRAPmail (PINK:WRAP) reached up 66.67% in morning trading to $.15 with 440K shares traded. WrapMail, Inc. is a publicly traded company that was incorporated in Florida in October 2005 with a Patent Application filed on the day of incorporation. The basic idea behind wrapmail is to utilize the facts that all businesses have websites and employees that send emails every day. These emails can become complete marketing tools and help promote, brand, sell and cross-sell in addition to drive traffic to the website and conduct research. WrapMail has thousands of corporate clients around the globe using its proprietary cloud software solution. WRAPmail (OTC:WRAP.ob - News) today announced that they have made available the first component of their webmail solution built in to the WRAPmail dashboard.

Radient Pharmaceuticals Corporation (OTCQX: RXPC) (PINK: RXPC) reached up 23.08% in morning trading to $.0032 with 19M shares traded. Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. Radient Pharmaceuticals Corporation (OTCQX: RXPC.PK - News) (Pinksheets: RXPC.PK - News) today announced it has signed a Regional Distributor Partner Agreement with Irvine-based TS Pharm, Inc.

Agenus Inc. (Nasdaq:AGEN) reached up 11.63% in morning trading to $.625 with 200K shares traded. Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Agenus Inc. (Nasdaq:AGEN - News) today announced positive results from a randomized, four-arm Phase 1 study of HerpV, a recombinant (off-the-shelf) therapeutic vaccine for the treatment of genital herpes, which included the Company's proprietary QS-21 Stimulon(R) adjuvant. The results were published in the peer-reviewed journal Vaccine.

For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com

About PennyTrader.com

PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.

Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report

PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE